Deoxycholic acid-functionalised nanoparticles for oral delivery of rhein

Eur J Pharm Sci. 2021 Apr 1:159:105713. doi: 10.1016/j.ejps.2021.105713. Epub 2021 Jan 13.

Abstract

Rhein (RH) is a candidate for the treatment of kidney diseases. However, clinical application of RH is impeded by low aqueous solubility and oral bioavailability. Deoxycholic acid-conjugated nanoparticles (DNPs) were prepared by ionic interaction for enhancing intestinal absorption by targeting the apical sodium-dependent bile acid transporter in the small intestine. Resultant DNPs showed relatively high entrapment efficiency (90.7 ± 0.73)% and drug-loading efficiency (6.5 ± 0.29)% with a particle size of approximately 190 nm and good overall dispersibility. In vitro release of RH from DNPs exhibited sustained and pH-dependent profiles. Cellular uptake and apparent permeability coefficient (Papp) of the DNPs were 3.25- and 5.05-fold higher than that of RH suspensions, respectively. An in vivo pharmacokinetic study demonstrated significantly enhanced oral bioavailability of RH when encapsulated in DNPs, with 2.40- and 3.33-fold higher Cmax and AUC0-inf compared to RH suspensions, respectively. DNPs are promising delivery platforms for poorly absorbed drugs by oral administration.

Keywords: Chitosan; Deoxycholic acid; Nanoparticles; Oral bioavailability; Rhein.

MeSH terms

  • Administration, Oral
  • Anthraquinones
  • Biological Availability
  • Deoxycholic Acid
  • Drug Carriers
  • Nanoparticles*
  • Particle Size

Substances

  • Anthraquinones
  • Drug Carriers
  • Deoxycholic Acid
  • rhein